Celeris - 500 Beiträge pro Seite

[toska]

Guten Morgen!


Es geht um die amerikanische Celeris: Eine Firma die Forschungs-
dienstleistungen (z. B. Datentransfer von Forschungsergebnissen),
sowie Outsourcing (z. B. Erstellung von Entwicklungsprofilen für neue
Produkte) fuer bio- und gentechnologisch arbeitende Firmen
zur Verfügung stellt. Man arbeitet mit Oracle an einer Internetplattform
auf der Forschungsdaten umgeschlagen und damit der Daten- und
Ergebnistransfer zwischen Forschung und Industrie beschleunigt
werden soll. Konkret soll die Plattform im Herbst 2000 an den Start
gehen. Die Firma verzeichnet stark sinkende Verluste und hofft das
vierte Quartal 2000 ev. positiv gestalten zu köennen.
Die Marktkapitalisierung betraegt derzeit ca. 8 Mill. €. Die Aktie wird
an der Nasdaq gehandelt; in D schwach in Berlin und in Frankfurt fast
gar nicht. (WKN 924855, Ticker: CRSC).
Wer hat mehr Infos zu Celeris? Ausserdem bin ich für Einschätzungen
der Zukunftsaussichten dankbar.

Einen erfolgreichen Tag wünscht
Toska

[toska]

Und noch was zum Schmunzeln:
In Berlin hat heute schon einer 40 Celeris-Aktien
im Gesamtwert von € 108 (Kurs derzeit € 2,70)
gekauft. Wenn das kein tolles Geschaeft ist!
Falls derjenige diese Zeilen liest, soll er doch
mal kurz erklaeren, wie er das mit den Gebuehren
bei einem solchen Geschaeft sieht, bzw. welchen
Broker er hat.

So long
T.

[ostblock]

Hallo Toska,

Schön daß sich noch jemand für Celeris interessiert. Zur Beschreibung von Celeris läßt sich noch
hinzufügen, daß der aktuelle Kurs so ca. dem Bargeldbestand und Buchwert/Aktie entspricht - dürfte
bei New Economy-Aktien eine ziemliche Seltenheit sein!

Den einzigen ausführlicheren Bericht zu CRSC laß ich im österr. "Börsen-Kurier" vom 24.2.2000, sehr lobend
und die Akte auch beim damaligen Stand von über 6 USD als "Schnäppchen" bezeichnend. "Obwohl es sich
bei Celeris um einen extrem volatilen und marktengen Wert handelt, ist aufgrund der Internetphantasie
ab 2001 ein KGV von 40 gerechtfertigt, woraus ein theoretisches Kurspotential von mehr als 80 USD
resultiert."

War zwar vor den großen Internet-Ausverkaug, aber dennoch! Stutzig macht mich allerdings die extrem karge
Info-Politik, die letzte News auf Yahoo zu CRSC stammt vom 17.5. Auch hätte der "Neartime-Zugang zu
klinischen Daten via Internet" laut "Börsen-Kurier" schon Ende Juni klappen sollen, was glaube ich nicht
passiert ist.

Grüße aus dem Osten,
O.

[toska]

Hallo ostblock!

Nachfolgend gebe ich Etwas wieder, das ich auf marketwatch.com
gefunden habe. Klingt nicht so gut. Es wird jetzt einfach Zeit, dass
Celeris mal seine Software auf den Markt bringt. Uebrigens ich bin
auch aus dem "ostblock" (Thueringen naemlich). Jetzt aber BW.

Gruss
T.



Celeris Corporation Reports Second Quarter Results

WEDNESDAY, JULY 26, 2000 6:30:00 PM EST

NASHVILLE, Tenn., Jul 26, 2000 (BUSINESS WIRE) -- Celeris Corporation CRSC, a provider of specialty clinical research services to
pharmaceutical, medical device and biotechnology companies, today announced results from operations for the second quarter and six months
ended June 30, 2000.

Revenues for the second quarter ended June 30, 2000, were $2.86 million, a 19% increase over revenues of $2.40 million in the second quarter
of 1999. Loss from continuing operations for the quarter was $994,000, or $0.32 per diluted share, compared with a loss from continuing
operations of $1.04 million, or $0.33 per diluted share, in the prior year period. The Company also announced a backlog of projects for clinical
studies management, data management and clinical monitoring services presently valued at approximately $4.5 million. Backlog is in addition to
the Company`s regulatory consulting business, which has historically generated approximately $1.0 million in revenue per quarter.

Revenues for the six months ended June 30, 2000, were $5.65 million, a 30% increase over revenues of $4.33 million in the first half of 1999.
Loss from continuing operations for the six months was $1.84 million, or $0.59 per diluted share, compared with a loss from continuing
operations of $2.23 million, or $0.71 per diluted share, in the prior year period.

Barbara A. Cannon, president and chief executive officer of Celeris Corporation, said, "Our results for the second quarter reflect increases in
both volume of revenue and number of clients served. We believe we will sustain this level of revenue production into the second half of 2000,
all the while actively seeking new opportunities to expand our revenue base and portfolio of device and pharmaceutical clients."

Ms. Cannon added, "Our Internet-based data management tools are in the late stages of development, and we expect to begin beta-testing
these tools with our active clients soon. A prototype version is now being used in demonstration with prospective clients and has been well
received."

In addition, on July 25, 2000, the Minnesota Supreme Court denied the Company`s petition for review of the Minnesota Court of Appeals`
decision related to the Company`s directors and officers insurance policies. The Court of Appeals decision held that the Company`s insurance
policies did not cover expenses and monetary liabilities associated with the Company`s pending securities litigation. There are no further appeals
available to the Company.

A listen-only simulcast of Celeris` second quarter conference call will be available online at www.celeriscorp.com or www.streetevents.com,
www.streetfusion.com or www.vcall.com on July 27, 2000, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately
two hours later and continue for 30 days.

Celeris Corporation is a provider of specialty clinical research services and information technology services that expedite and streamline the
clinical trial and regulatory submission process for pharmaceutical, medical device and biotechnology manufacturers.

This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include statements of intent, belief or
current expectations of Celeris Corporation and its management. Such forward-looking statements are not guarantees of future results and
involve risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements.
Risks and uncertainties that may cause such differences include, but are not limited to the uncertainty of market acceptance of the Company`s
new clinical research services; changes in the Company`s backlog including potential cancellation, delay or change in the scope of client contracts
for clinical research services; the Company`s dependence on a single client for a material portion of the Company`s revenues; the timing of the
development of the Company`s Internet capabilities, and the related market acceptance thereof; and other risk factors detailed in the Company`s
Securities and Exchange Commission filings, including the Company`s Form 10-K for the year ended December 31, 1999.

CELERIS CORPORATION AND SUBSIDIARIES
Unaudited Condensed Consolidated Statements of Operations
(In thousands, except per share data)

Three Months EndedSix Months Ended
June 30,June 30,
----------------------------------
2000199920001999
----------------------------
Revenue$ 2,859$ 2,399$ 5,648$ 4,332
Cost of sales1,8971,6443,8543,017
----------------------------

Gross Profit9627551,7941,315
Operating expenses2,0441,9303,8213,859
----------------------------

Income (loss) from operations(1,082)(1,175)(2,027)(2,544)
Interest income, net88139187309
----------------------------
Income (loss) from
continuing operations(994)(1,036)(1,840)(2,235)

Gain (loss) on disposal of
discontinued operations--200--400
----------------------------

Net income (loss)$(994)$(836)$(1,840)$(1,835)
============================

Basic and diluted
income (loss) per common
share1)
Continuing operations$ (0.32)$ (0.33)$ (0.59)$ (0.71)
Discontinued operations--0.06--0.13
----------------------------
$ (0.32)$ (0.27)$ (0.59)$ (0.58)
============================

Basic and diluted
weighted average
shares outstanding(1)3,129,978 3,134,883 3,127,196 3,137,333

(1) Adjusted to reflect a reverse three-for-one stock split on
July 29, 1999.


CELERIS CORPORATION AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Dollars In thousands)

June 30,Dec. 31,
20001999
----------------
ASSETS
Current Assets:
Cash, cash equivalents, restricted cash,
and short-term investments$5,744$8,965
Accounts receivable, net of allowance
of $513 and $343, respectively3,4131,774
Other current assets3931,052
----------------

Total current assets9,55011,791
Net furniture, fixtures and equipment1,5451,388
----------------

Total Assets$ 11,095$ 13,179
================

LIABILITIES AND SHAREHOLDERS` EQUITY

Current Liabilities:
Accounts payable and accrued expenses$808$1,068
Deferred revenue and payables453446
Accrued compensation156453
Current portion of capital
lease obligation118--
Net current liabilities of
discontinued operations1,0911,196
----------------
Total current liabilities2,6263,163


Long-term portion of capital
lease obligation186--

Shareholders` Equity:
Common stock, $0.01 par value -
13,511,111 shares authorized; and
3,178,655 and 3,119,646 shares
issued and outstanding, respectively3231
Additional paid-in capital67,62367,518
Accumulated deficit(59,372)(57,533)
----------------
Total shareholders` equity8,28310,016
----------------

Total Liabilities and
Shareholders` Equity$ 11,095$ 13,179
================

CONTACT:Celeris Corporation, Nashville
Paul R. Johnson, 615/341-0223

URL:http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.

Distributed via COMTEX.

[ostblock]

Hallo Toska,

Danke für die Quartalsergebnisse! Schaut nicht sehr dynamisch aus. Immerhin ging aber die Aktie in
Amerika am Freitag gut, keine Ahnung ob das etwas zu bedeuten hat.

Im neuen "Economist" (29.7.) gibts übrigens einen Artikel über "contract research organisations" (CROs, Tenor
viel Potential aber viele Unsicherheiten und vor allem viele Anbieter, CRSC leider nicht erwähnt.

Schöne Grüße,
O.